查詢結果分析
來源資料
相關文獻
- 晚期鼻咽癌同步化學放射治療之研究--臺中榮總之經驗
- Hemoglobin Level during Chemoradiation Therapy Predicts Treatment Outcome in Nasopharyngeal Cancer
- Concurrent Weekly Cisplatin and Radiotherapy Plus Adjuvant Chemotherapy for Nasopharyngeal Cancer--A Preliminary Study
- Concurrent Chemoradiotherapy Using Cisplatin and 5-Fluorouracil alone or with Paclitaxel Followed by Adjuvant Cisplatin and 5-Fluorouracil in Nasopharyngeal Carcinoma
- 協助一位鼻咽癌病患接受同步化學放射治療的護理經驗
- 鼻咽癌病人接受同步化學治療及質子放射線治療之護理經驗
- Orbital Invasion in Nasopharyngeal Carcinoma: Evaluation with Computed Tomography and Magnetic Resonance Imaging
- 上頜掀開術切除局部復發之鼻咽癌--三例報告
- 中醫脈診儀應用於鼻咽癌患者接受放射線治療全程之研究
- Detection of Human Papilloma Virus and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma by Polymerase Chain Reaction
頁籤選單縮合
| 題 名 | 晚期鼻咽癌同步化學放射治療之研究--臺中榮總之經驗=Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Carcinoma--Experience in Taichung Veterans General Hospital |
|---|---|
| 作 者 | 林進清; 詹建勝; 曾顯群; 翁益強; 高忠恕; 王麗鈴; | 書刊名 | 放射治療與腫瘤學 |
| 卷 期 | 4:2 1997.06[民86.06] |
| 頁 次 | 頁93-100 |
| 分類號 | 416.879 |
| 關鍵詞 | a同步的; 化學放射治療; 鼻咽癌; Concurrent; Chemoradiotherapy; Nasopharyngeal carcinoma; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 目的:鼻咽癌是一種好發於中國南方的癌症,傳統的治療方式是放射治療,其五 年存活率約 50%,近年來癌症治療趨勢是合併式療,鼻咽癌對放射線和化學治療都很敏感, 本研究探討同步放射化學治療對晚期鼻咽癌的之可行性、療效及副作用。材料與方法:本研 究共收集 80 位晚期鼻咽癌,其中 76 例 (95%) 屬於第四期。 最初 19 例接受傳統式分次 放射治療方式,即每天照射一次,每次 1.8-2.0 Gy,每週照射五次; 其次 61 例接受我們 自行設計的部份高分次放射治療方式:第一、五、六週每天上下午各照一次 1.5 Gy, 第二 、三、四週每天照射一次每次 1.8 Gy,總濟量為 72 Gy/45 分次 /6 週, 如果遇到假日或 機器故障,則利用週六補照或將劑量分攤於其他治療日,務必於六週內給予 72 Gy。同步化 學治療採用 cisplatin 和 5-FU,在放療中第一和第五週同時給予二次化療。 結果:80 例 中有 77 例 (96%) 腫瘤完全緩解, 3 例腫瘤部份緩解佔 4%,腫瘤反應率高達 100%! 病人 的急性副作用,主要是白血球降低、口腔黏膜發炎反應 (56% 達第三級 )、體重減輕... 等 。 有 5 例第二次化療因毒性反應須延後一週給予,有 2 例第二次化療只打一半,有 2 例 拒絕第二次化療。 放射治療因毒性反應中斷超過一週以上者有 7 例, 其中 1 例只照射至 55.5 Gy 後,就拒絕繼續放療。迄今追蹤時間已 39 至 66 個月 (中值追蹤時間 48 個月 ) ,結果 23 例已死亡,57 人仍存活。 死亡病例中,17 例因鼻咽癌而死 (16 例死於遠處轉 移 ),總計目前治療失敗者有 24 例, 單獨鼻咽部復發 3 例,鼻咽部和頸部淋巴同時復發 者 4 例,1 例發生頸部淋巴復發合併遠處轉移, 其他 16 例都是遠處轉移,四年鼻咽部控 制率 87.5%,頸部控制率 91.8%,遠處轉移控制率 76.2%,四年總存活率為 71.9%,四年無 病存活率為 66.3%。結論:同步化學放射治療對晚期鼻咽癌是可行且很有效的治療方式,遠 處轉移是治療失敗的主要原因,放療後再追加輔助性化學治療,以減少遠處轉移發生,提高 存活率,值得進一步研究。 |
| 英文摘要 | Purpose: Nasopharyngeal carcinoma (NPC) is a radio- and chemosensitive tumor. We evaluate the feasibility, response and toxicities of concurrent chemoradiotherapy for advanced NPC. Materials and Methods: A total of 80 patients with advanced NPC (95% belong to AJCC stage IV) were treated by concurrent chemoradiotherapy. Radiotherapy was delivered using a telecobalt unit and 10 MV X-rays and by conventional fractionation (1.8-2.0 gy/fraction, 5 fractions a week) for 19 patients and partially hperfractionated accelerated schedule (1.5 Gy B.I.D. x 1 week + 1.8 Gy Q.D. x 3 weeks + 1.5 Gy B.I.D. x 2 weeks) for 61 patients. Chemotherapy with cisplatin and 5-FU were given concurrently during the first and fifth weeks of radiotherapy. Results: The major toxicities were mucositis, leucopenia, weight loss, and skin reaction. the 2nd cycle concurrent chemotherapy should be delayed for one week in 5 patients. Two patients refused the 2nd cycle chemotherapy and another 2 patients received incomplete dose of 2nd cycle chemotherapy. Seven patients interrupted radiotherapy for more than one week due to toxicities. One patient refused further radiotherapy after 55.5 Gy. Complete response was noted in 77 cases (96%) and partial response 4%, with an overall response rate of 100%. After a median follow-up time of 4 years (39-66 months), the nasopharynx disease-free, neck diseasefree, and distant metastasis disease-free survivals are 87.5%, 91.8%, and 76.25 irrespectively. The 4-year overall survival and disease-free survival are 71.95 and 66.3%. Patients who failed were due to distant metastases. Conclusion: Our data indicated that concurrent chemoradiotherapy for advanced NPC is both feasible and effective, with acceptable toxicities. Post-radiation adjuvant chemotherapy to eradicate suclinical micrometastasis should be further studied. |
本系統中英文摘要資訊取自各篇刊載內容。